2025-06-17-Jefferies-回放与要点_默沙东（MRK）佳达修关键意见领袖电话会议要点_9页_890kb

Gardasil KOL Call Summary

ACIP Vote Expectations:
The ACIP committee is expected to recommend a 1-dose HPV vaccination schedule for ages 9-14yo with approximately 50% probability. This recommendation was anticipated by the KOL based on data supporting improved adherence and similarity in genital wart prevention outcomes between 1- and 2-dose schedules, though extending to a broader age range is less likely (~25%).

Support for 1-dose:
Akash Tewari noted that reduced doses enhance real-world compliance and genital wart data similarities support the recommendation. Analysts emphasize that data gaps in cancer prevention may influence interpretations, but the focus on adherence and similar efficacy minimizes bias against 1-dose, despite potential differences in HPV strains covered.

Committee Dynamics:
The ACIP is ideologically polarized, with skeptical members possibly pushing for 1-dose to minimize exposure. However, conventional clinicians like Dr. Meissner may support it if data merits. The vote was deemed less politically charged than COVID, with historical precedent (e.g., reducing doses from 3 to 2 in 2016) and stronger existing safety data for Gardasil compared to early COVID trials.

Practical Rollout:
Communication of guidelines to 1,000+ clinicians may face legal risks from payer inconsistencies and liability if off-label use occurs after ACIP endorsement. Adoption is easier for 9yo patients due to less stigma; however, some systems may delay implementation pending FDA label changes or contract terms affecting reimbursement and pricing.

Company Valuation and Risk Overview

Merck & Co. Inc (MRK): Valuation based on DCF model, risks include R&D, competition, and regulatory factors; equity analysts assign a BUY rating based on DCF and peer relative valuations.

BioNTech SE (BNTX): Equity view grounded in discounted cash flow analysis; principal risks involve clinical and regulatory uncertainties, along with commercial execution challenges.

Moderna, Inc (MRNA): Holds a HOLD rating due to high risks involving climical development delays, manufacturing hurdles, increased competition, and regulatory uncertainty.

Pfizer Inc (PFE): Valuation supported by DCF and DCF/PE/PEG models; risks span late-stage failures, manufacturing issues, reimbursement obstacles, competition, and M&A-related volatility, though currently retains a BUY rating.

Analyst certifications confirm personal views and compliance with performance incentives tied to firm-wide investment banking income.